Sisram Medical Ltd. (stock code: 01696) has agreed with Fosun Wanbang (Jiangsu) — an indirect wholly owned subsidiary of Fosun Pharma, Sisram’s controlling shareholder — to extend both their New Sublicense Agreement and the accompanying New Promotional Services Agreements to 31 December 2026. The original expiry date for each contract was 30 September 2026.

The extension keeps all commercial terms and the respective maximum transaction amounts unchanged:

• New Sublicense Agreement: capped at US$2.71 million for the period 1 January 2026–31 December 2026 (of which about US$1.38 million had been utilised by 31 August 2026). • New Promotional Services Agreements: capped at US$3.79 million for the same period (approximately US$2.08 million utilised to 31 August 2026).

According to Chapter 14A of the Hong Kong Listing Rules, the transactions constitute continuing connected transactions. The highest applicable percentage ratio, calculated on an aggregated basis, exceeds 0.1 % but is below 5 %, subjecting the parties only to reporting, annual review and announcement requirements; shareholder approval and circular issuance are not required.

The board — including independent non-executive directors — views the three-month extension as commercially reasonable, enabling uninterrupted import, distribution and marketing of the product while leveraging Fosun Wanbang’s distribution network and operational capacity. Internal controls, including regular utilisation monitoring and annual audits, remain in place to ensure compliance with the agreed caps and listing regulations.